Non-homologous end-joining factor 1 (NHEJ1), also known as Cernunnos or XRCC4-like factor (XLF), is a protein that in humans is encoded by the NHEJ1 gene.[1] XLF was originally discovered as the protein mutated in five patients with growth retardation, microcephaly, and immunodeficiency.[2] The protein is required for the non-homologous end joining (NHEJ) pathway of DNA repair. Patients with XLF mutations also have immunodeficiency due to a defect in V(D)J recombination, which uses NHEJ to generate diversity in the antibody repertoire of the immune system. XLF interacts with DNA ligase IV and XRCC4 and is thought to be involved in the end-bridging or ligation steps of NHEJ. The yeast (Saccharomyces cerevisiae) homolog of XLF is Nej1.[3]
In contrast to the profound immunodeficiency phenotype of XLF deletion in humans, deletion of XLF alone has a mild phenotype in mice.[4] However, combining a deletion of XLF with deletion of the ATM kinase causes a synthetic defect in NHEJ, suggesting partial redundancy in the function of these two proteins in mice.[5]
Structure
XLF is structurally similar to XRCC4, existing as a constitutive dimer with an N-terminal globular head domain, an alpha-helical stalk, and an unstructured C-terminal region (CTR).[6]
Interactions
XLF has been shown to interact with XRCC4,[7] and with Ku protein,[8] and it can also interact weakly with DNA.[9][10] Co-crystal structures of XLF and XRCC4 suggest that the two proteins can form hetero-oligomers via head-to-head interaction of alternating XLF and XRCC4 subunits.[11][12][13] These XRCC4-XLF filaments have been proposed to bridge DNA prior to end ligation during NHEJ. Formation of XRCC4-XLF oligomers can be disrupted by interaction of the C-terminal domain of XRCC4 with the BRCT domain of DNA ligase IV.[11]
Hematopoietic stem cell aging
Deficiency of NHEJ1 in mice leads to premature aging of hematopoietic stem cells as indicated by several lines of evidence including evidence that long-term repopulation is defective and worsens over time.[14] Using a human induced pluripotent stem cell model of NHEJ1 deficiency, it was shown that NHEJ1 has an important role in promoting survival of the primitive hematopoietic progenitors.[15] These NHEJ1 deficient cells possess a weak NHEJ1-mediated repair capacity that is apparently incapable of coping with DNA damages induced by physiological stress, normal metabolism, and ionizing radiation.[15]
↑Buck D, Malivert L, de Chasseval R, Barraud A, Fondanèche MC, Sanal O, Plebani A, Stéphan JL, Hufnagel M, le Deist F, Fischer A, Durandy A, de Villartay JP, Revy P (Jan 2006). "Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly". Cell. 124 (2): 287–99. doi:10.1016/j.cell.2005.12.030. PMID16439204.
↑Callebaut I, Malivert L, Fischer A, Mornon JP, Revy P, de Villartay JP (May 2006). "Cernunnos interacts with the XRCC4 x DNA-ligase IV complex and is homologous to the yeast nonhomologous end-joining factor Nej1". The Journal of Biological Chemistry. 281 (20): 13857–60. doi:10.1074/jbc.C500473200. PMID16571728.
↑Andres SN, Modesti M, Tsai CJ, Chu G, Junop MS (Dec 2007). "Crystal structure of human XLF: a twist in nonhomologous DNA end-joining". Molecular Cell. 28 (6): 1093–101. doi:10.1016/j.molcel.2007.10.024. PMID18158905.
↑Lu H, Pannicke U, Schwarz K, Lieber MR (Apr 2007). "Length-dependent binding of human XLF to DNA and stimulation of XRCC4.DNA ligase IV activity". The Journal of Biological Chemistry. 282 (15): 11155–62. doi:10.1074/jbc.M609904200. PMID17317666.
↑ 15.015.1Tilgner K, Neganova I, Singhapol C, Saretzki G, Al-Aama JY, Evans J, Gorbunova V, Gennery A, Przyborski S, Stojkovic M, Armstrong L, Jeggo P, Lako M (2013). "Brief report: a human induced pluripotent stem cell model of cernunnos deficiency reveals an important role for XLF in the survival of the primitive hematopoietic progenitors". Stem Cells. 31 (9): 2015–23. doi:10.1002/stem.1456. PMID23818183.
Further reading
Pastwa E, Malinowski M (May 2007). "Non-homologous DNA end joining in anticancer therapy". Current Cancer Drug Targets. 7 (3): 243–50. doi:10.2174/156800907780618284. PMID17504121.
Buck D, Malivert L, de Chasseval R, Barraud A, Fondanèche MC, Sanal O, Plebani A, Stéphan JL, Hufnagel M, le Deist F, Fischer A, Durandy A, de Villartay JP, Revy P (Jan 2006). "Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly". Cell. 124 (2): 287–99. doi:10.1016/j.cell.2005.12.030. PMID16439204.
Ahnesorg P, Smith P, Jackson SP (Jan 2006). "XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining". Cell. 124 (2): 301–13. doi:10.1016/j.cell.2005.12.031. PMID16439205.
Callebaut I, Malivert L, Fischer A, Mornon JP, Revy P, de Villartay JP (May 2006). "Cernunnos interacts with the XRCC4 x DNA-ligase IV complex and is homologous to the yeast nonhomologous end-joining factor Nej1". The Journal of Biological Chemistry. 281 (20): 13857–60. doi:10.1074/jbc.C500473200. PMID16571728.
Revy P, de Villartay JP (2006). "[Cernunnos, a novel DNA repair factor essential for the immune system]". Médecine Sciences. 22 (6–7): 569–70. doi:10.1051/medsci/20062267569. PMID16828027.
Cantagrel V, Lossi AM, Lisgo S, Missirian C, Borges A, Philip N, Fernandez C, Cardoso C, Figarella-Branger D, Moncla A, Lindsay S, Dobyns WB, Villard L (Apr 2007). "Truncation of NHEJ1 in a patient with polymicrogyria". Human Mutation. 28 (4): 356–64. doi:10.1002/humu.20450. PMID17191205.
Lu H, Pannicke U, Schwarz K, Lieber MR (Apr 2007). "Length-dependent binding of human XLF to DNA and stimulation of XRCC4.DNA ligase IV activity". The Journal of Biological Chemistry. 282 (15): 11155–62. doi:10.1074/jbc.M609904200. PMID17317666.
Wu PY, Frit P, Malivert L, Revy P, Biard D, Salles B, Calsou P (Nov 2007). "Interplay between Cernunnos-XLF and nonhomologous end-joining proteins at DNA ends in the cell". The Journal of Biological Chemistry. 282 (44): 31937–43. doi:10.1074/jbc.M704554200. PMID17720816.